AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9880180 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/TCP coated tibial component
Number of subjects: 36
Study 9880180 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tibial component
Number of subjects: 36
Study 9880180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 7997386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose‐1,6‐diphosphate 125 mg/kg
Number of subjects: 0
Study 7997386 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1.3 ml/kg
Number of subjects: 0
Study 3348162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading at 128 mmol/d
Number of subjects: 10
Study 3348162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading at 256 mmol/d
Number of subjects: 10
Study 3348162 — intervention group
Group type: COMPARATOR
Intervention: Control period (low-Na diet)
Number of subjects: 10
Study 30108107 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Number of subjects: 40
Study 27621583 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation (n = 24)
Number of subjects: 46
Study 27621583 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation (n = 22)
Number of subjects: 46
Study 24736773 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - 12 weeks of squat MST at 85-90% of 1RM
Number of subjects: 30
Study 24736773 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - encouraged to follow ACSM exercise guidelines
Number of subjects: 30
Study 22268911 — intervention group
Group type: EXPERIMENTAL
Intervention: Uppercase, rhyme, or category‐membership judgments about words with immediate recall after every 3 or 8 processing judgments.
Number of subjects: 0
Study 22268911 — intervention group
Group type: EXPERIMENTAL
Intervention: Surprise immediate recall of 8‐item lists.
Number of subjects: 0
Study 20087376 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins and 7 mg Zinc daily for 10 weeks
Number of subjects: 30
Study 20087376 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins only
Number of subjects: 30
Study 18174214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex: 2 x 2 mg per day)
Number of subjects: 9
Study 18174214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 9
Study 15486010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg kg(‐1) at induction
Number of subjects: 62
Study 15486010 — intervention group
Group type: COMPARATOR
Intervention: No fentanyl
Number of subjects: 62
Study 15486010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (fentanyl and no fentanyl)
Number of subjects: 62
Study 12452874 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U BTX‐A (Botox, Allergan, Inc.)
Number of subjects: 320
Study 12452874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 12452874 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A
Number of subjects: 320
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets containing 60 mg of elemental iron
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets containing 120 mg of elemental iron
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets containing 180 mg of elemental iron
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin capsules containing pure ferrous salt
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate tablets
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered ferrous sulphate tablets
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron tablets distributed by the NNAPP
Number of subjects: 115
Study 10326325 — intervention group
Group type: EXPERIMENTAL
Intervention: Excipients added to pure ferrous sulphate salts
Number of subjects: 115
Study 8622045 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation chemotherapy regimens (F-MACHOP or MACOP-B)
Number of subjects: 90
Study 1933116 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured surface silicone implants
Number of subjects: 53
Study 1933116 — intervention group
Group type: COMPARATOR
Intervention: Smooth surface silicone implants
Number of subjects: 53
Study 7310012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine (0.1 mg in saline)
Number of subjects: 15
Study 7310012 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 15
Study 30192638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg intravenously)
Number of subjects: 0
Study 30192638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30192638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 28064380 — intervention group
Group type: EXPERIMENTAL
Intervention: PFN-a surgery
Number of subjects: 89
Study 28064380 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drainage
Number of subjects: 89
Study 28064380 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI < 25 kg/m2
Number of subjects: 89
Study 28064380 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission specific gravity of urine > 1.020
Number of subjects: 89
Study 28064380 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission albumin < 30 g/L
Number of subjects: 89
Study 25545810 — intervention group
Group type: EXPERIMENTAL
Intervention: pf‐PVA
Number of subjects: 90
Study 25545810 — intervention group
Group type: EXPERIMENTAL
Intervention: oc‐PVA
Number of subjects: 90
Study 25545810 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐PVA
Number of subjects: 90
Study 25711249 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Chernousov modified Nissen fundoplication (CMNF)
Number of subjects: 243
Study 25711249 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total fundoplication
Number of subjects: 243
Study 21135547 — intervention group
Group type: EXPERIMENTAL
Intervention: short-term low dietary protein intake (DPI) supplemented with keto acids
Number of subjects: 40
Study 21135547 — intervention group
Group type: COMPARATOR
Intervention: normal dietary protein intake (NP)
Number of subjects: 40
Study 19335534 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 2368
Study 19335534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD)
Number of subjects: 2368
Study 19335534 — intervention group
Group type: COMPARATOR
Intervention: Metformin (Met)/Thiazolidinediones (TZD)
Number of subjects: 2368
Study 17991260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 1 mg.kg(‐1)
Number of subjects: 108
Study 17991260 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 40 mg.kg(‐1)
Number of subjects: 108
Study 17991260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal diclofenac and paracetamol
Number of subjects: 108
Study 15790458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel (PT)
Number of subjects: 302
Study 15790458 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 302
Study 12473557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 86
Study 9481597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 9481597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sibutramine
Number of subjects: 235
Study 9481597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sibutramine
Number of subjects: 235
Study 9481597 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine
Number of subjects: 235
Study 9481597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 15 mg sibutramine
Number of subjects: 235
Study 7638922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic examination of the knee joint
Number of subjects: 193
Study 7638922 — intervention group
Group type: COMPARATOR
Intervention: Clinical tests of stability (Lachmann)
Number of subjects: 193
Study 2515494 — intervention group
Group type: COMPARATOR
Intervention: Oral zinc acetate (6-month study)
Number of subjects: 26
Study 2515494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6-month study)
Number of subjects: 26
Study 2515494 — intervention group
Group type: COMPARATOR
Intervention: Oral pergolide mesylate (3-month crossover study)
Number of subjects: 26
Study 2515494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3-month crossover study)
Number of subjects: 26
Study 369642 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy with excision of the ulcer (HSVE)
Number of subjects: 56
Study 369642 — intervention group
Group type: COMPARATOR
Intervention: Standard Billroth I partial gastrectomy (BI)
Number of subjects: 56
Study 369642 — intervention group
Group type: COMPARATOR
Intervention: Both HSVE and BI
Number of subjects: 56
Study 31735650 — intervention group
Group type: EXPERIMENTAL
Intervention: We Immunize program (2-hour enhanced training and tailored monthly feedback for 6 months)
Number of subjects: 62
Study 31735650 — intervention group
Group type: COMPARATOR
Intervention: Control group (1-hour live immunization update only)
Number of subjects: 62
Study 30786315 — intervention group
Group type: COMPARATOR
Intervention: Mechanical lithotripsy
Number of subjects: 32
Study 30786315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided laser lithotripsy
Number of subjects: 32
Study 30075405 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (at least one session)
Number of subjects: 271
Study 30075405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 271
Study 26443023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 20898
Study 26443023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20898
Study 24217196 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 probiotic
Number of subjects: 26
Study 24217196 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 26
Study 22231904 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 703
Study 22231904 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI-based models and composite outcome (LDA or ACR50)
Number of subjects: 703
Study 18813910 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (six treatments: positioning, manual hyperinflation, and suctioning in each 24-hour period while on mechanical ventilation)
Number of subjects: 144
Study 18813910 — intervention group
Group type: COMPARATOR
Intervention: Standard medical/nursing care (Control Group)
Number of subjects: 144
Study 17503315 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 30 mg monthly alone
Number of subjects: 71
Study 17503315 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 30 mg monthly in combination with rofecoxib (up to 50 mg bid daily)
Number of subjects: 71
Study 15066461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of CEE and calcium
Number of subjects: 300
Study 15066461 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 300
Study 11806623 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin tablets 300 mg once a day (Rx)
Number of subjects: 100
Study 11806623 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid tablets 875+125 mg twice a day (Acx)
Number of subjects: 100
Study 9569566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 57
Study 9569566 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 57
Study 8059778 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 490
Study 3197622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endoscopic and surgical intervention
Number of subjects: 728
Study 3197622 — intervention group
Group type: COMPARATOR
Intervention: Purely endoscopic procedures
Number of subjects: 728
Study 3197622 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic papillotomy (EPT)
Number of subjects: 728
Study 30817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle multidomain intervention + omega-3 supplementation (MI + O3)
Number of subjects: 1679
Study 30817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (O3)
Number of subjects: 1679
Study 30817982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle multidomain intervention (MI)
Number of subjects: 1679
Study 30817982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1679
Study 27902529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) at 70% estimated V˙O2peak for 30 min
Number of subjects: 20
Study 27902529 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 20
Study 25931293 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration and antibiotics
Number of subjects: 22
Study 25931293 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 22
Study 23957767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day family constellation seminar (active participant and observing participant)
Number of subjects: 208
Study 23957767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day family constellation seminar
Number of subjects: 208
Study 21156772 — intervention group
Group type: EXPERIMENTAL
Intervention: A+‐ICD
Number of subjects: 249
Study 21156772 — intervention group
Group type: COMPARATOR
Intervention: DR‐ICD
Number of subjects: 249
Study 21156772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both A+‐ICD and DR‐ICD
Number of subjects: 249
Study 18667809 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training, 3 times a week for 4 weeks
Number of subjects: 11
Study 18667809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra computer training)
Number of subjects: 11
Study 17312647 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation (EC)
Number of subjects: 102
Study 17312647 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy (IS)
Number of subjects: 102
Study 12956654 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus minocycline microspheres
Number of subjects: 271
Study 12956654 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 271
Study 12956654 — intervention group
Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 271
Study 15919490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 252
Study 10604693 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial-impregnated catheters (minocycline and rifampin)
Number of subjects: 124
Study 10604693 — intervention group
Group type: COMPARATOR
Intervention: Control catheters
Number of subjects: 124
Study 8953600 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemzar)
Number of subjects: 189
Study 8953600 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5‐FU)
Number of subjects: 189
Study 2030024 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Number of subjects: 123
Study 2030024 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 123
Study 7237920 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath hold at total lung capacity for 15 seconds
Number of subjects: 8
Study 7237920 — intervention group
Group type: COMPARATOR
Intervention: Breath hold at total lung capacity for 0 seconds
Number of subjects: 8
Study 30715534 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change techniques (BCTs) used in the exercise intervention
Number of subjects: 0
Study 30715534 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30974049 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 0
Study 30974049 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 0
Study 30974049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data of Revefenacin 88 μg and 175 μg
Number of subjects: 0
Study 30974049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27690626 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme prime
Number of subjects: 80
Study 27690626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate prime
Number of subjects: 80
Study 27690626 — intervention group
Group type: COMPARATOR
Intervention: Control (not pregnant)
Number of subjects: 80
Study 27690626 — intervention group
Group type: COMPARATOR
Intervention: Control (pregnant)
Number of subjects: 80
Study 25523285 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 199
Study 25523285 — intervention group
Group type: COMPARATOR
Intervention: antipsychotics
Number of subjects: 199
Study 24790178 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) plus ezetimibe (10 mg) daily
Number of subjects: 6245
Study 24790178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6245
Study 22534815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks.
Number of subjects: 16
Study 22534815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks (phase II portion).
Number of subjects: 16
Study 22534815 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment related grade-3/4 toxicities.
Number of subjects: 16
Study 19922127 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based data management system
Number of subjects: 105
Study 19922127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of trial personnel
Number of subjects: 105
Study 17179250 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS) 1.5 mg
Number of subjects: 150
Study 17179250 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg IV
Number of subjects: 150
Study 17179250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV
Number of subjects: 150
Study 15049459 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg + ALB 400 mg
Number of subjects: 103
Study 15049459 — intervention group
Group type: COMPARATOR
Intervention: DEC 6 mg/kg + ALB placebo
Number of subjects: 103
Study 11493282 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin at a dose of 85 IU anti‐Xa/kg
Number of subjects: 15
Study 11493282 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin at a bolus of 100 IU anti‐Xa/kg
Number of subjects: 15
Study 11493282 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin at a standard dose of 70 IU anti‐Xa/kg
Number of subjects: 15
Study 9489907 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole and 150 mg TAP
Number of subjects: 95
Study 9489907 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 95
Study 7817384 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (Group I)
Number of subjects: 37
Study 31621257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture 20 min once a day (Group A)
Number of subjects: 140
Study 31621257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture 30 min once a day (Group B)
Number of subjects: 140
Study 31621257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture 20 min once every 2 days (Group C)
Number of subjects: 140
Study 31621257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture 30 min once every 2 days (Group D)
Number of subjects: 140
Study 28505961 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dual-task condition
Number of subjects: 19
Study 28505961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task condition
Number of subjects: 19
Study 28505961 — intervention group
Group type: COMPARATOR
Intervention: Single-task condition
Number of subjects: 19
Study 25771294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep position modification device (active)
Number of subjects: 86
Study 25771294 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene advice (control)
Number of subjects: 86
Study 24188203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized high-dose budesonide (BUD group)
Number of subjects: 118
Study 24188203 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 118
Study 21979395 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP)
Number of subjects: 147
Study 21979395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) plus alverine citrate
Number of subjects: 147
Study 18466681 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 25 mg daily
Number of subjects: 280
Study 18466681 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 50 mg daily
Number of subjects: 280
Study 18466681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 18466681 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 (both dosages)
Number of subjects: 280
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1: zidovudine (AZT), lamivudine (3TC), indinavir (IDV)
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2: zidovudine (AZT), lamivudine (3TC), ritonavir (RTV)
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3: didanosine (DDI), estavudine (D4T), indinavir (IDV)
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 4: didanosine (DDI), estavudine (D4T), ritonavir (RTV)
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1
Number of subjects: 98